Heavy Bleeding During Perimenopause

Heavy bleeding during perimenopause often reflects a hormonal imbalance. In early perimenopause, estrogen can remain high while progesterone falls, allowing the uterine lining to overgrow. Understanding that mechanism helps explain changing periods, but it does not establish the cause of every heavy bleed.

Why heavy periods in perimenopause are so common — and so confusing

A period that suddenly becomes heavier can feel alarming, especially when a woman expects to have fewer periods and less hormonal activity. Changes in menstrual bleeding are among the most common signs of perimenopause, yet they do not follow one predictable course. Cycles may shorten or lengthen, flow may increase or decrease, and periods may disappear temporarily. Common does not mean easy to interpret. The explanation begins with irregular ovulation, but understanding the mechanics is only part of the task.

The counterintuitive hormonal mechanics behind heavy bleeding

In a regularly ovulating cycle, ovarian follicles produce estrogen, which builds the uterine lining. After ovulation, the follicle forms a temporary structure called the corpus luteum. This structure produces progesterone, which stabilizes the lining and helps organize its eventual shedding. Ovulation therefore does more than release an egg. It creates the progesterone-producing phase that counterbalances estrogen’s growth signal.

Early perimenopause disrupts that sequence because ovulation becomes less reliable. Without regular ovulation, progesterone production declines, even while estrogen remains active or spikes. The lining can keep growing without adequate counterbalance. This is the sense in which early perimenopause can be “estrogen-dominant.” The term describes estrogen’s effect relative to progesterone.

Why would estrogen rise as ovarian reserve declines? The pituitary responds by producing more follicle-stimulating hormone, or FSH, to stimulate the remaining follicles. In early perimenopause, those follicles can over-respond and produce elevated estradiol, a form of estrogen. Shorter cycles, breast tenderness, worsened premenstrual symptoms, and heavier periods can therefore accompany relative estrogen excess.

Later, as follicles stop responding to FSH, estradiol falls. Before that point, however, prolonged estrogen exposure without enough progesterone can produce endometrial hyperplasia, a distinct condition involving overgrowth of the uterine lining. These hormone changes explain how it can develop, but bleeding alone cannot show whether it has.

Where heavy bleeding fits in the perimenopause timeline

Heavy bleeding is especially common in early-to-mid perimenopause, when periods still happen but are harder to predict. The STRAW+10 classification, or Stages of Reproductive Aging Workshop framework, organizes reproductive aging primarily around menstrual changes, with FSH as a supporting measure. Age alone does not determine the stage. Perimenopause usually begins in a woman’s 40s and often lasts several years, but the pattern of her cycles says more about her stage than her age does.

Stage -2, early perimenopause, begins with noticeable variation in cycle length. Heavy or prolonged bleeding may emerge with sleep disruption, worsening PMS, breast tenderness, mood changes, or intermittent brain fog. Stage -1, late perimenopause, brings longer stretches without periods. Bleeding generally becomes less frequent as the final period approaches, but a long gap can still end in a very heavy bleed. Less frequent does not always mean lighter.

The final menstrual period can only be identified retrospectively, after twelve consecutive months without a period. Until then, bleeding after a gap may be part of the transition, though the pattern alone cannot show what caused it. What else could explain it?

Other conditions that cause heavy bleeding and how to tell them apart

Ovulatory dysfunction is the most common explanation for heavy perimenopausal bleeding, but clinicians also consider structural and non-structural causes. The PALM-COEIN classification organizes that investigation. PALM covers polyps, adenomyosis, leiomyoma or fibroids, and malignancy or hyperplasia. COEIN covers coagulopathy, ovulatory dysfunction, endometrial causes, iatrogenic or treatment-related causes, and causes not yet classified. The framework prevents a premature conclusion based on age.

Symptoms offer diagnostic clues. Adenomyosis involves uterine lining tissue growing into the uterine wall and can cause heavy bleeding with menstrual pain that worsens with age. Pelvic pain that comes with the bleeding suggests a structural cause, which imaging can help check for. Fibroids and polyps can also cause or worsen bleeding. Hyperplasia differs because the lining itself overgrows, and although most cases are benign, some forms are precancerous.

Both an underactive and an overactive thyroid can disrupt bleeding, while PCOS can cause irregular or absent ovulation outside the perimenopausal transition. Clotting disorders also belong in the differential diagnosis. Medication and contraceptive history add another layer because anticoagulants, hormonal contraceptives, and IUD placement can alter bleeding patterns. These possibilities explain why a clinician asks about more than periods.

Endometrial cancer is a less likely explanation, but persistent bleeding and bleeding after menopause require evaluation. Risk findings also need careful interpretation. Tian et al., in J Health Popul Nutr (2024), identified benign endometrial lesions, endometrial thickness ≥ 10 mm, BMI ≥ 25, and IUD placement as independent risk factors for abnormal uterine bleeding in perimenopausal women. Those associations reinforce the need to investigate the cause of each change in an individual woman.

When heavy bleeding requires immediate attention versus planned evaluation

Soaking through a pad or tampon every hour for several consecutive hours, or passing clots larger than a quarter, needs to be checked promptly by a clinician. These are concrete signs of heavy menstrual bleeding. If the situation is an emergency, seek emergency care.

Any bleeding after twelve consecutive months without a period also needs to be checked. It should not be assumed to be another perimenopausal fluctuation. Bleeding that keeps happening needs to be checked for the same reason, even when there does not seem to be much blood. Amount is not the only warning sign. Timing and persistence can make bleeding clinically concerning.

For periods that are heavier than before but do not meet those thresholds, tracking and discussion at the next appointment are appropriate. New irregularity or a sudden shortening or lengthening of cycles also deserves documentation. Note fatigue, weakness, and hair loss as well. These can suggest iron depletion, even when bleeding itself seems manageable and ferritin has not fallen below the laboratory minimum. Whether care is urgent or planned, knowing what the evaluation is meant to establish can make that encounter more useful.

What a workup for heavy perimenopausal bleeding actually involves

A useful workup asks both why bleeding is happening and what it has done to the body. Transvaginal ultrasound is a first-line imaging tool used to look for structural causes and measure endometrial thickness. It is widely available and cost-effective. Its findings help guide whether biopsy or hysteroscopy is needed. The thickness association in the Tian study supports investigating the lining, but an ultrasound measurement still needs interpretation in the wider clinical picture.

Thyroid testing, including TSH and related markers, looks for a thyroid problem that could cause abnormal bleeding and can be treated. Iron studies and ferritin assess depletion after significant blood loss, particularly when fatigue or hair loss is present. A result that helps explain how the ovaries work cannot show what ongoing bleeding has done to the body.

FSH and estradiol can help describe the transition, but both fluctuate substantially. FSH may rise and then fall back to a premenopausal range, while estradiol can be high, normal, or low at different times. One blood draw is not a verdict. Pyne et al., in Bull World Health Organ (2024), note that FSH can fall within the normal range during perimenopause itself. A history of changing cycles and symptoms still matters when a result is normal.

Progesterone is relevant because reduced production after irregular ovulation helps explain endometrial overgrowth. AMH addresses another question by reflecting the remaining ovarian follicle pool and helping predict time to menopause, particularly at low values. Neither replaces an assessment of the bleeding. Targeted testing tells more when it is paired with records of cycle length, flow, clots, and when symptoms happen. Those records show whether a result fits a pattern that keeps happening or comes from one unusual day.

Treatment options for heavy perimenopausal bleeding

Most heavy perimenopausal bleeding responds to treatment once its cause is understood. Options include non-hormonal medicines, hormonal treatment, procedures, and correction of iron depletion. The choice depends on severity, the diagnosis, and the woman’s preferences and circumstances. Treatment is not one-size-fits-all. A clinician can explain which options address the cause and which primarily reduce the bleeding.

Tranexamic acid, also called Lysteda, and NSAIDs are non-hormonal options used during periods to reduce heavy bleeding. NSAIDs reduce prostaglandin-driven blood flow and can reduce flow when taken during the heaviest days. Hormonal treatment works through a different route. Combined oral contraceptives, a levonorgestrel IUD, and oral progestogen can stabilize the uterine lining when ovulatory dysfunction is responsible. Oral progestogen may be used cyclically or continuously, depending on clinical judgment and the stage of the transition.

A levonorgestrel IUD delivers progestogen locally to the lining, addressing the missing progesterone counterbalance. That differs from removing a structural source of bleeding. Hysteroscopic removal of a polyp or fibroid targets the growth itself and does not affect ovarian function. Other procedural options include endometrial ablation and hysterectomy when medical treatment has not worked or structural disease requires intervention. Ablation is appropriate only after childbearing is complete and malignancy has been ruled out.

Iron repletion is also part of treatment when heavy bleeding has depleted iron stores. The effects extend beyond the period itself. Iron deficiency anemia can impair energy, cognition, and overall health, so reducing blood loss does not complete the clinical task. Fibroids, adenomyosis, polyps, and hyperplasia also have distinct management pathways and may require subspecialty referral. For treatment to work, the cause needs to be found through history, testing, and imaging, since the bleeding pattern alone is too little to go on when choosing a remedy.

How tracking changes over time improves both understanding and care

For a woman preparing for care, the practical step is to build a record across cycles. Cycle length, flow, clot size, and the timing of symptoms are useful details to document. Early changes may be small, with periods coming a few days earlier or later or becoming a little heavier or lighter. Patterns emerge through comparison. A series of shortening cycles asks a different clinical question from one unusually heavy period after a long gap.

Clinical results can become part of that record. When tests are repeated as part of care, changes in FSH, estradiol, progesterone, and AMH can add context to the menstrual history, while thyroid and iron results address different possible causes and consequences. Serial ultrasound measurements can likewise inform decisions about further investigation. No single measure explains the whole transition. The value lies in relating the findings to one another rather than treating every result as a standalone answer.

Tracking also makes the clinical conversation more precise. Instead of reporting that periods have become “different,” a woman can show when the change began, whether it persisted, and how it affected daily life. That detail helps challenge misattribution and supports informed treatment decisions with a clinician. It is not a reason to delay evaluation when warning signs appear.